Commentary|Videos|September 9, 2025
Reviewing Key Data in Resectable and ROS1+ NSCLC With Drs Florez and Sabari
Narjust Florez, MD, and Joshua K. Sabari, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.
Advertisement
Narjust Florez, MD, of Dana-Farber Brigham Cancer Center, and Joshua K. Sabari, MD, of NYU Langone Health’s Perlmutter Cancer Center, sit down with Chandler Park, MD, FACP, of Norton Cancer Institute, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.
Advertisement
Related to this article
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.
The NMPA approved T-DXd after neoadjuvant therapy, based on DESTINY-Breast05 data, in which the agent lowered the risk of recurrence or death vs T-DM1.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma
4
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
5